NCT04629157View on ClinicalTrials.gov

The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19

NACompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions

This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19Covid19

Interventions

DEVICE

Innova Lateral Flow Device

The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.

Trial Locations (2)

Unknown

Alder Hey in the Park, Liverpool

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors

lead

Alder Hey Children's NHS Foundation Trust

OTHER

NCT04629157 - The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19 | Biotech Hunter | Biotech Hunter